{"id":"W2902530914","doi":"10.1093/annonc/mdy517","title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":795,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Triple-negative breast cancer; Pembrolizumab; Metastatic breast cancer; Cohort; Oncology; Internal medicine; Breast cancer; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006374138,0.000203238,0.0008608242,0.0001195536,0.0001343173,0.000003774355,0.0002128679,0.0000890158,0.0003591264],"category_scores_gemma":[0.0000875361,0.0001296898,0.000317444,0.0004002827,0.0005312828,0.00005420063,0.00003440893,0.000100849,0.000001052625],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009807641,"about_ca_system_score_gemma":0.0006546073,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002382971,"about_ca_topic_score_gemma":0.0008633992,"domain_scores_codex":[0.9983003,0.0002309856,0.0006488647,0.0002891818,0.0002208972,0.0003098163],"domain_scores_gemma":[0.9980381,0.0002100099,0.000571084,0.0004184167,0.0006921516,0.00007025407],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2742167,0.01843414,0.04137537,0.0002574289,0.01087141,0.00001711434,0.01685878,0.000003720839,0.04823326,0.00005629359,0.02275869,0.5669171],"study_design_scores_gemma":[0.2016055,0.2408361,0.3127547,0.0005024321,0.00301289,0.0002268952,0.002842128,0.0004452532,0.1946326,0.00048765,0.04206168,0.0005921448],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901263,0.0007494268,0.00004141766,0.004168656,0.0002297887,0.003858562,0.0002961647,0.00001952531,0.0005102014],"genre_scores_gemma":[0.9963993,0.000685634,0.0001215563,0.001388615,0.000132614,0.0004351469,0.000008966687,0.00002798462,0.0008001365],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5663249,"threshold_uncertainty_score":0.5288598,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07573474290946053,"score_gpt":0.4318296695631981,"score_spread":0.3560949266537375,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}